<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03519945</url>
  </required_header>
  <id_info>
    <org_study_id>16596</org_study_id>
    <secondary_id>I6T- MC-AMAP</secondary_id>
    <secondary_id>2017 004092 31</secondary_id>
    <nct_id>NCT03519945</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study designed to evaluate the long-term efficacy and safety of mirikizumab in
      participants with moderately to severely active ulcerative colitis (UC).
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 27, 2018</start_date>
  <completion_date type="Anticipated">August 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 23, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants in Clinical Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Clinical remission based on the modified Mayo Score (MMS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Endoscopic Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Endoscopic remission based on the MMS Endoscopic Subscores (ES).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants in Corticosteroid-free Remission</measure>
    <time_frame>Week 52</time_frame>
    <description>Percentage of participants in corticosteroid-free remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Mucosal Healing at Week 52</measure>
    <time_frame>Week 52</time_frame>
    <description>Mucosal healing based on a histologic disease activity index.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Related Quality of Life: Inflammatory Bowel Disease Questionnaire (IBDQ) Score</measure>
    <time_frame>Baseline to Week 52</time_frame>
    <description>Health Related Quality of Life based on IBDQ score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>UC Symptoms: Numeric Rating Score</measure>
    <time_frame>Week 160</time_frame>
    <description>UC symptoms based on numeric rating score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who are Hospitalized Due to UC</measure>
    <time_frame>Baseline to Week 160</time_frame>
    <description>Percentage of participants who are hospitalized due to UC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Undergo UC Surgeries Including Colectomy</measure>
    <time_frame>Baseline to Week 160</time_frame>
    <description>Percentage of participants who undergo UC surgeries including colectomy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>Mirikizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mirikizumab administered subcutaneously (SC).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mirikizumab</intervention_name>
    <description>Administered SC.</description>
    <arm_group_label>Mirikizumab</arm_group_label>
    <other_name>LY3074828</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria

               -  Participants from Study AMAC (NCT02589665) or AMBG (NCT #:TBD) who have had at
                  least one study drug administration and have not had early termination of study
                  drug.

               -  Female participants must agree to contraception requirements.

          -  Exclusion Criteria

               -  Participants must not have developed a new condition, including cancer in the
                  originator study.

               -  Participants must not have any important infections including, but not limited
                  to, hepatitis B, hepatitis C, HIV/AIDS, and active tuberculosis (TB) during
                  either originator study

               -  Participants may not have received surgery for UC in the originator study or are
                  likely to require surgery for treatment of UC during the study.

               -  Participants must not have developed adenomatous polyps during the originator
                  study that have not been removed prior to the start of this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or</last_name>
    <phone>1-317-615-4559</phone>
    <email>ClinicalTrials.gov@lilly.com</email>
  </overall_contact>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2018</study_first_submitted>
  <study_first_submitted_qc>May 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Inflammatory Bowel Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com.
This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

